Translating genomics for precision cancer medicine.

The Human Genome Project not only provided the essential reference map for the human genome but also stimulated the development of technology and analytic tools to process massive quantities of genomic data. As a result of this project, new technologies for DNA sequencing have improved in efficiency and cost by more than a millionfold over the past decade, and these technologies can now be routinely applied at a cost of less than $5,000 per genome. Although the application of these technologies in cancer genomics research has continued to contribute to basic discoveries, opportunities for translating them for individual patients have also emerged. This is especially important in clinical cancer research, where genetic alterations in a patient's tumor may be matched to molecularly targeted therapies. In this review, we discuss the integration of cancer genomics and clinical oncology and the opportunity to deliver precision cancer medicine.

[1]  A. McKenna,et al.  Exome and whole genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity , 2013, Nature Genetics.

[2]  N. Rosen,et al.  Tumor adaptation and resistance to RAF inhibitors , 2013, Nature Medicine.

[3]  Rashmi Kanagal-Shamanna,et al.  Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. , 2013, The Journal of molecular diagnostics : JMD.

[4]  C. von Kalle,et al.  BRAF inhibition in refractory hairy-cell leukemia. , 2012, The New England journal of medicine.

[5]  N. Rosenfeld,et al.  Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA , 2013, Nature.

[6]  B. Druker,et al.  Chronic myelogenous leukemia , 2001, Current opinion in oncology.

[7]  G. Getz,et al.  A Genomics-Based Classification of Human Lung Tumors , 2013, Science Translational Medicine.

[8]  Aik Choon Tan,et al.  Patient-derived tumour xenografts as models for oncology drug development , 2012, Nature Reviews Clinical Oncology.

[9]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[10]  Nallasivam Palanisamy,et al.  Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA , 2011, Science Translational Medicine.

[11]  Gary D Bader,et al.  Comprehensive identification of mutational cancer driver genes across 12 tumor types , 2013, Scientific Reports.

[12]  Jeffrey A. Porter,et al.  Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth. , 2012, Cancer discovery.

[13]  T. Golub,et al.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.

[14]  S. Nicosia,et al.  One mouse, one patient paradigm: New avatars of personalized cancer therapy. , 2014, Cancer letters.

[15]  M. Guyer,et al.  Charting a course for genomic medicine from base pairs to bedside , 2011, Nature.

[16]  P. Hirth,et al.  Vemurafenib: the first drug approved for BRAF-mutant cancer , 2012, Nature Reviews Drug Discovery.

[17]  M. Hicks,et al.  Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience. , 2011, The oncologist.

[18]  C. Sawyers.  The cancer biomarker problem , 2008, Nature.

[19]  C. Sotiriou,et al.  Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? , 2007, Nature Reviews Cancer.

[20]  David Chen,et al.  ESR1 ligand binding domain mutations in hormone-resistant breast cancer , 2013, Nature Genetics.

[21]  J. Leamon,et al.  Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping. , 2013, The Journal of molecular diagnostics : JMD.

[22]  A. Chinnaiyan,et al.  Functionally Recurrent Rearrangements of the MAST Kinase and Notch Gene Families in Breast Cancer , 2011, Nature Medicine.

[23]  R. H. Levin,et al.  The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. , 1965, Blood.

[24]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[25]  Y. Totoki,et al.  Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma , 2014, Hepatology.

[26]  A. Ferrando,et al.  Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia , 2011, Nature Genetics.

[27]  L. Pasqualucci,et al.  Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation , 2011, The Journal of experimental medicine.

[28]  Wei Yan,et al.  Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. , 2011, Cancer cell.

[29]  A. Iafrate,et al.  Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers , 2012, Science Translational Medicine.

[30]  Elaine R. Mardis,et al.  A decade’s perspective on DNA sequencing technology , 2011, Nature.

[31]  C. Bloomfield,et al.  Chromosomal abnormalities in acute lymphoblastic leukemia. , 1981, Cancer research.

[32]  A. Papavassiliou,et al.  Seeing the future of cancer-associated transcription factor drug targets. , 2011, JAMA.

[33]  K. Flaherty,et al.  BRAF, a target in melanoma , 2010, Cancer.

[34]  C. Sander,et al.  Genome Sequencing Identifies a Basis for Everolimus Sensitivity , 2012, Science.

[35]  D. Tindall,et al.  Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  A. Butte,et al.  A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. , 2013, Cancer discovery.

[37]  J. Byrd,et al.  Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL). , 2013 .

[38]  J. Rowley.  A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining , 1973, Nature.

[39]  Gang Shao,et al.  A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. , 2013, Cancer discovery.

[40]  R. Bernards,et al.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.

[41]  A. Shaw,et al.  Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  S. Antoniu.  Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease? , 2011, Expert opinion on therapeutic targets.

[43]  J. Wisell,et al.  Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma , 2013 .

[44]  S. Paik,et al.  Development of the 21-gene assay and its application in clinical practice and clinical trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[46]  A. Børresen-Dale,et al.  The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.

[47]  Alex M. Fichtenholtz,et al.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.

[48]  Dirk Schadendorf,et al.  Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .

[49]  Ryan D. Morin,et al.  Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. , 2012, Blood.

[50]  M. Ladanyi,et al.  Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .

[52]  Mari Mino-Kenudson,et al.  EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. , 2012, Cancer discovery.

[53]  H. Clevers,et al.  Growing Self-Organizing Mini-Guts from a Single Intestinal Stem Cell: Mechanism and Applications , 2013, Science.

[54]  Yuki Togashi,et al.  RET, ROS1 and ALK fusions in lung cancer , 2012, Nature Medicine.

[55]  Ryan D. Morin,et al.  Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. , 2012, Cancer cell.

[56]  Tatiana G. Kutateladze,et al.  Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[57]  I. Tannock,et al.  Phase III Trials of Targeted Anticancer Therapies: Redesigning the Concept , 2013, Clinical Cancer Research.

[58]  Johannes G. Reiter,et al.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.

[59]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[60]  C. Ong,et al.  Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. , 2012, Cancer discovery.

[61]  P. Nowell,et al.  A minute chromosome in human chronic granulocytic leukemia , 1960 .

[62]  Hiroyuki Konishi,et al.  The PIK3CA gene is mutated with high frequency in human breast cancers , 2004, Cancer biology & therapy.

[63]  Benjamin J. Raphael,et al.  Mutational landscape and significance across 12 major cancer types , 2013, Nature.

[64]  S. Pradervand,et al.  Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression , 2013, Clinical Cancer Research.

[65]  N. Girard,et al.  New driver mutations in non-small-cell lung cancer. , 2011, The Lancet. Oncology.

[66]  R. Schilsky,et al.  Role of randomized phase III trials in an era of effective targeted therapies , 2012, Nature Reviews Clinical Oncology.

[67]  Juliane C. Dohm,et al.  Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.

[68]  Renato Martins,et al.  Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. , 2014, The Journal of molecular diagnostics : JMD.

[69]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .

[70]  Funda Meric-Bernstam,et al.  Building a personalized medicine infrastructure at a major cancer center. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[72]  Doron Lipson,et al.  Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies , 2012, Nature Medicine.

[73]  Li Ding,et al.  The Pediatric Cancer Genome Project , 2012, Nature Genetics.

[74]  M. Barbacid,et al.  Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. , 1984, Science.

[75]  Alan S. Perelson,et al.  Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.

[76]  Somasekar Seshagiri,et al.  Oncogenic ERBB3 mutations in human cancers. , 2013, Cancer cell.

[77]  Daniel A. Haber,et al.  Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways , 2004, Science.

[78]  T. Eberlein,et al.  Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .

[79]  Alan Mackay,et al.  FGFR1 Emerges as a Potential Therapeutic Target for Lobular Breast Carcinomas , 2006, Clinical Cancer Research.

[80]  E. Lander,et al.  Lessons from the Cancer Genome , 2013, Cell.

[81]  K. Pienta,et al.  Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[82]  A. Sivachenko,et al.  A Landscape of Driver Mutations in Melanoma , 2012, Cell.

[83]  Nickolay A. Khazanov,et al.  Identification of targetable FGFR gene fusions in diverse cancers. , 2013, Cancer discovery.

[84]  S. Ogawa,et al.  Oncogenic mutations of ALK kinase in neuroblastoma , 2008, Nature.

[85]  M. Meyerson,et al.  Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer , 2011, PloS one.

[86]  Nikhil Wagle,et al.  Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  Spyro Mousses,et al.  A transforming mutation in the pleckstrin homology domain of AKT1 in cancer , 2007, Nature.

[88]  Mari Mino-Kenudson,et al.  Acquired resistance to crizotinib from a mutation in CD74-ROS1. , 2013, The New England journal of medicine.

[89]  H. Howe,et al.  The Occurrence of Rare Cancers in U.S. Adults, 1995–2004 , 2010, Public health reports.

[90]  J. Kaiser.  Biomedicine. Rare cancer successes spawn 'exceptional' research efforts. , 2013, Science.

[91]  G. Parmigiani,et al.  Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing , 2012, Science Translational Medicine.

[92]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[93]  Joshua F. McMichael,et al.  Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.

[94]  Young Lim Choi,et al.  EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. , 2010, The New England journal of medicine.

[95]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[96]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[97]  G. Bubley,et al.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.

[98]  Kiran C. Bobba,et al.  The genetic basis of early T-cell precursor acute lymphoblastic leukaemia , 2012, Nature.

[99]  Hongbing Zhang,et al.  Pathogenesis of Tuberous Sclerosis Subependymal Giant Cell Astrocytomas: Biallelic Inactivation of TSC1 or TSC2 Leads to mTOR Activation , 2004, Journal of neuropathology and experimental neurology.

[100]  S. Dhanasekaran,et al.  Characterization of KRAS rearrangements in metastatic prostate cancer. , 2011, Cancer discovery.

[101]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[102]  Javed Siddiqui,et al.  Activating ESR1 mutations in hormone-resistant metastatic breast cancer , 2013, Nature Genetics.

[103]  T. Mizuno,et al.  Isolation of transforming sequences of two human lung carcinomas: structural and functional analysis of the activated c-K-ras oncogenes. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[104]  S. Gabriel,et al.  Advances in understanding cancer genomes through second-generation sequencing , 2010, Nature Reviews Genetics.

[105]  S. Nelson,et al.  Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance , 2012, Nature Communications.

[106]  Daniel F. Hayes,et al.  Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer , 2013 .

[107]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.

[108]  L. Tanoue,et al.  Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer , 2012 .

[109]  A. Sivachenko,et al.  Sequence analysis of mutations and translocations across breast cancer subtypes , 2012, Nature.

[110]  Shashikant Kulkarni,et al.  Assuring the quality of next-generation sequencing in clinical laboratory practice , 2012, Nature Biotechnology.

[111]  Erin M. Olson,et al.  The ethical use of mandatory research biopsies , 2011, Nature Reviews Clinical Oncology.

[112]  R. Arceci.  Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing , 2012 .

[113]  Marc Ladanyi,et al.  Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. , 2010, The New England journal of medicine.

[114]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[115]  M. Meyerson,et al.  Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. , 2011, Cancer discovery.

[116]  Li Ding,et al.  Activating HER2 mutations in HER2 gene amplification negative breast cancer. , 2013, Cancer discovery.

[117]  C. Perou,et al.  The genomic landscape of breast cancer as a therapeutic roadmap. , 2013, Cancer discovery.

[118]  Lewis C Cantley,et al.  The APL paradigm and the "co-clinical trial" project. , 2011, Cancer discovery.

[119]  A. Tefferi,et al.  BRAF mutations in hairy-cell leukemia. , 2011, The New England journal of medicine.

[120]  Chandra Sekhar Pedamallu,et al.  Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. , 2013, Cancer research.

[121]  D. Ho,et al.  HIV-1 at 25 , 2008, Cell.

[122]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.